Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


13.07.2026

1 Am J Clin Pathol
4 Ann Hematol
2 Blood
3 Bone Marrow Transplant
8 Br J Haematol
2 Cancer Chemother Pharmacol
1 Cancer Lett
3 Leuk Lymphoma
2 Leuk Res
1 Leukemia
1 PLoS Genet
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. PADMANABHA N, Sperling AS, Morgan EA, Michaels PD, et al
    Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.
    Am J Clin Pathol. 2026;166:aqag080.
    PubMed         Abstract available


    Ann Hematol

  2. HADIPOUR K, Abdiaei E, Miri-Aliabad G
    Favorable outcome in TCF3::HLF-positive pediatric B-cell acute lymphoblastic leukemia without classic metabolic complications: A case report.
    Ann Hematol. 2026 Jul 10. doi: 10.1007/s00277-026-07166.
    PubMed         Abstract available

  3. CATINI ME, Garibotto M, Morelli MC, Tagliafico A, et al
    Severe hypereosinophilia and eosinophilic myocarditis during secondary plasma cell leukemia: evidence of a paraneoplastic manifestation of aggressive myeloma evolution.
    Ann Hematol. 2026 Jul 9. doi: 10.1007/s00277-026-07172.
    PubMed         Abstract available

  4. TOKURA T, Wakita S, Fukunaga K, Nagata Y, et al
    Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.
    Ann Hematol. 2026 Jul 7. doi: 10.1007/s00277-026-07158.
    PubMed         Abstract available

  5. HURVITZ N, Amitai I, Yurkovski IL, Tvito A, et al
    MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.
    Ann Hematol. 2026;105:320.
    PubMed         Abstract available


    Blood

  6. BROCHTEL S, Schneider C, Muller M, Villinger C, et al
    USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.
    Blood. 2026 Jul 8:blood.2025031845. doi: 10.1182/blood.2025031845.
    PubMed         Abstract available

  7. WANG Y, Chen S, Liu S, Liang Z, et al
    FLT3-ITD scaffolds PKCiota-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML.
    Blood. 2026;148:213-228.
    PubMed         Abstract available


    Bone Marrow Transplant

  8. LUSSANA F, Rizzuto G, Piciocchi A, Oldani E, et al
    Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.
    Bone Marrow Transplant. 2026 Jul 8. doi: 10.1038/s41409-026-02966.
    PubMed        

  9. SWOBODA R, Labopin M, Kroger N, Stelljes M, et al
    Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.
    Bone Marrow Transplant. 2026 Jul 8. doi: 10.1038/s41409-026-02932.
    PubMed         Abstract available

  10. WANG M, Zhang G, Guo W, Zhang H, et al
    CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML.
    Bone Marrow Transplant. 2026;61:873-882.
    PubMed         Abstract available


    Br J Haematol

  11. VALCARCEL B, Utsunomiya A, Otsuka M, Miyahara M, et al
    Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.
    Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70494.
    PubMed         Abstract available

  12. TODA Y, Jo T, Arai Y, Harada K, et al
    Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.
    Br J Haematol. 2026;209:210-221.
    PubMed         Abstract available

  13. ZHANG ZX, Zhang L, Lu AD, Zhang LP, et al
    Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.
    Br J Haematol. 2026;209:172-179.
    PubMed         Abstract available

  14. RAMPOTAS A, Naylor-Layland G, Brown C, Alabdulkarim A, et al
    Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.
    Br J Haematol. 2026;209:160-171.
    PubMed         Abstract available

  15. FERRARA F
    Azacitidine-venetoclax in unfit acute myeloid leukaemia: One size does not fit all.
    Br J Haematol. 2026;209:391-392.
    PubMed         Abstract available

  16. BHATIA P, Sharun S, Palla S, Brady SW, et al
    Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.
    Br J Haematol. 2026;209:54-62.
    PubMed         Abstract available

  17. ZHOU J, Kui X, Huang D, Zhang X, et al
    AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2026;209:84-95.
    PubMed         Abstract available

  18. IRIYAMA N, Takahashi N, Fujimaki K, Ono T, et al
    Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.
    Br J Haematol. 2026 Jul 9. doi: 10.1111/bjh.70678.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  19. ABUMIYA M, Abe K, Watanabe A, Takahashi N, et al
    Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.
    Cancer Chemother Pharmacol. 2026;96:72.
    PubMed         Abstract available

  20. CHARAMIS J, Katzilakis N, Stiakaki E, Kyriakidis I, et al
    Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.
    Cancer Chemother Pharmacol. 2026;96:69.
    PubMed         Abstract available


    Cancer Lett

  21. SU Y, Xu X, Yang G, Chen B, et al
    Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies.
    Cancer Lett. 2025;633:218014.
    PubMed         Abstract available


    Leuk Lymphoma

  22. TAN L, Wang X, Zhao Y, Li J, et al
    Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.
    Leuk Lymphoma. 2026 Jul 6:1-4. doi: 10.1080/10428194.2026.2689467.
    PubMed        

  23. ORVAIN C, Othus M, Byelykh M, Schoch G, et al
    Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.
    Leuk Lymphoma. 2026 Jul 6:1-13. doi: 10.1080/10428194.2026.2695317.
    PubMed         Abstract available

  24. TIBIRICA DOS REIS D, Silvestri EF, Farah de Oliveira EJ, Chiedde M, et al
    Leukemia mortality analysis in the pediatric population in Sao Paulo state, Brazil, 2000-2019.
    Leuk Lymphoma. 2026 Jul 5:1-9. doi: 10.1080/10428194.2026.2691908.
    PubMed         Abstract available


    Leuk Res

  25. SENICHKINA D, Pukhalskaia T, Bogdanova D, Platonova E, et al
    Bioluminescent xenograft model of acute myeloid leukemia for immunotherapy preclinical studies.
    Leuk Res. 2026;168:108272.
    PubMed         Abstract available

  26. LATAGLIATA R, Pugliese N, Lame D, Cristiano G, et al
    Association of hypomethylating agents +?venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.
    Leuk Res. 2026;167:108255.
    PubMed         Abstract available


    Leukemia

  27. SIMON F, Al-Sawaf O
    Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
    Leukemia. 2026 Jul 7. doi: 10.1038/s41375-026-03012.
    PubMed        


    PLoS Genet


  28. Retraction: The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
    PLoS Genet. 2026;22:e1012224.
    PubMed        


    PLoS One

  29. HAN HJ, Choi K, Suh HS
    Correction: Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study.
    PLoS One. 2026;21:e0353299.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum